CoChat

Paclitaxel–Hyaluronic NanoConjugates Prolong Overall Survival in a Preclinical Brain Metastases of Breast Cancer Model

Open access
Mittapalli, Rajendar K., Liu, Xinli, Adkins, Chris E., Nounou, Mohamed I., Bohn, Kaci A., Terrell, Tori B., Qhattal, Hussaini S., Geldenhuys, Werner J., Palmieri, Diane, Steeg, Patricia S., Smith, Quentin R., Lockman, Paul R. · 2013 · Molecular Cancer Therapeutics
Cited by 101

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Brain (central nervous system; CNS) metastases pose a life-threatening problem for women with advanced metastatic breast cancer. It has recently been shown that the vasculature within preclinical brain metastasis model markedly restricts paclitaxel delivery in approximately 90% of CNS lesions. Therefore to improve efficacy, we have developed an ultra-small hyaluronic acid (HA) paclitaxel nanoconjugate (∼5 kDa) that can passively diffuse across the leaky blood–tumor barrier and then be taken up into cancer cells (MDA–MB–231Br) via CD44 receptor–mediated endocytocis. Using CD44 receptor–mediated endocytosis as an uptake mechanism, HA-paclitaxel was able to bypass p-glycoprotein–mediated efflux on the surface of the cancer cells. In vitro cytoxicity of the conjugate and free paclitaxel were similar in that they (i) both caused cell-cycle arrest in the G2–M phase, (ii) showed similar degrees of apoptosis induction (cleaved caspase), and (iii) had similar IC50 values when compared with paclitaxel in MTT assay. A preclinical model of brain metastases of breast cancer using intracardiac injections of Luc-2 transfected MDA–MB–231Br cells was used to evaluate in vivo efficacy of the nanoconjugate. The animals administered with HA–paclitaxel nanoconjugate had significantly longer overall survival compared with the control and the paclitaxel-treated group (P < 0.05). This study suggests that the small molecular weight HA–paclitaxel nanoconjugates can improve standard chemotherapeutic drug efficacy in a preclinical model of brain metastases of breast cancer. Mol Cancer Ther; 12(11); 2389–99. ©2013 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-13-0132

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Promotion of microtubule assembly in vitro by taxol

    SCHIFF, P. B., FANT, J., & HORWITZ, S. B. (1979) · Nature · doi:10.1038/277665a0 · Cited by 3,600 · cited 2×

    “HA-paclitaxel conjugates brain metastatic cells cytotoxicity Paclitaxel acts by binding and stabilizing the microtubules, which ultimately results in a G2-M arrest of the cell-cycle (35, 36).”

Show all 1 references

Cited by

See all 101

Metadata

Authors
Mittapalli, R. K., Liu, X., Adkins, C. E., Nounou, M. I., Bohn, K. A., Terrell, T. B., Qhattal, H. S., Geldenhuys, W. J., Palmieri, D., Steeg, P. S., Smith, Q. R., & Lockman, P. R.
Venue
Molecular Cancer Therapeutics
Published
2013-11-01
Volume
12
Issue
11
Pages
2389-2399
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2113238094
Cited by
101
References
1
FWCI
3.95
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Paclitaxel–Hyaluronic NanoConjugates Prolong Overall Survival in a Preclinical Brain Metastases of Breast Cancer Model. https://app.cochat.ai/papers/10.1158/1535-7163.mct-13-0132
The paper
Mittapalli, R. K., Liu, X., Adkins, C. E., Nounou, M. I., Bohn, K. A., Terrell, T. B., Qhattal, H. S., Geldenhuys, W. J., Palmieri, D., Steeg, P. S., Smith, Q. R., & Lockman, P. R. (2013). Paclitaxel–Hyaluronic NanoConjugates Prolong Overall Survival in a Preclinical Brain Metastases of Breast Cancer Model. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-13-0132

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.